The lab-scale system will allow researchers to study and culture stem cells in suspension
Glasgow, UK: REPROCELL Europe Ltd today announced exclusive distribution rights to a single-use reactor series for stem cell culture in 11 European countries*. The ABLE Biott Bioreactor System is a lab-scaled bioreactor that offers a new way for stem cell researchers to study and culture pluripotent stem cells.
“We are excited to offer our customers the chance to access this innovative new bioreactor, which is ideal for the culture of pluripotent stem cells” said Dr David Bunton, CEO at REPROCELL Europe Ltd. “The product has been rapidly and widely adopted by stem cell scientists in Japan and the US, with the recent CE marking now enabling its use in Europe”.
REPROCELL is pleased to announce that the first patient has been registered and the test article administered at Nagoya University in the Phase II clinical trial of the regenerative medicine product Stemchymal®.
Dates: 19-20 February 2020
Venue: Copthorne Tara, London, United Kingdom
REPROCELL Europe’s CSO Professor Stefan Przyborski will giving the keynote address on 3D cell culture at this year’s SMi 4th Annual Conference London, UK. There Prof Przyborski will also be showcasing REPROCELL’s range of Alvetex products for 3D cell culture.
A recent study by researchers from REPROCELL found that IBD patients display different drug absorption profiles to healthy individuals. This is the first time that drug absorption has been estimated using inflamed GI tissue from this patient group. A similar study, performed by Keio University, estimated drug absorption in healthy areas of GI tissue from ulcerative colitis (UC) donors.
Glasgow, UK: REPROCELL (Biopta) today announced that they can predict test article permeability using gastrointestinal (GI) resections from Inflammatory Bowel Disease (IBD) donors. This service, which is first of its kind to market, will allow ADME/DMPK scientists to estimate compound permeability in living human IBD tissue.
Glasgow, UK: REPROCELL (Biopta) today announced the successful publication of a novel study in pharmacology and genomics to improve strategies for the development of precision medicines. The study – performed in collaboration with the NHS, academia and Scottish companies Fios Genomics, Systemic, and Aridhia – used human living lung tissue from Chronic Obstructive Pulmonary Disease (COPD) donors to explain inter-patient variation in drug efficacy.
BELTSVILLE, MD. (PRWEB) NOVEMBER 12, 2019: REPROCELL Inc. a stem cell and drug discovery company has announced today that they have been selected by Lantern Pharma to provided preclinical screening and drug sensitivity for its portfolio of oncology drugs. The collaboration is designed to obtain millions of data points using panels of unique and genetically edited cell lines from various tumors. The data generated from these studies will help Lantern’s AI platform to generate the biological and genetic basis for drug positioning and maximum drug efficacy. Lantern believes this will help bring oncology therapies to patients more efficiently and affordably than traditional R&D efforts.
Maryland, September 2019: The Maryland based REPROCELL Inc. subsidiary, REPROCELL USA Inc. announces that they have received a $292,580 grant from the Maryland Stem Cell Research Fund (MSCRF).
Yokohama, Japan, & San Carlos, California, USA — REPROCELL, Inc., and NeuCyte, Inc., today announced a new distributorship.
Although NeuCyte has direct sales in North America, this new distributorship will grant REPROCELL customers access to NeuCyte's pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons (iNs), supplied with astroglia, media and supplements. These components come in kit formats so the user can set up well-defined, highly functional in vitro co-culture systems for compound screening, disease modeling and neurotoxicity assessment.
Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).